Could a 10-Minute Test Stop Unnecessary Antibiotic Prescribing? Paul Kase, CCO - Lumos Diagnostics
Notes de l’épisode
In this episode of Diagnosing Dx, David Filby is joined by Paul Kase, Chief Commercial Officer at Lumos Diagnostics.
Paul brings 30 years of healthcare experience, including more than 20 years in rapid point-of-care diagnostics. His history with FebriDx stretches back to its earliest development, and he now leads commercialisation as Lumos enters a major new phase following its US CLIA waiver.
Paul explains how FebriDx uses two host-response biomarkers to help differentiate bacterial from non-bacterial infections from a finger-stick blood sample in around 10 minutes, without instrumentation.
We also discuss antibiotic stewardship, reimbursement, integrating novel tests into existing clinical workflows, and the commercial strategy Lumos is using to drive adoption across urgent care and primary care.
Key takeaways:
🔹 Why the CLIA waiver represents such an important commercial milestone for FebriDx
🔹 How CRP and MxA are used to differentiate bacterial from non-bacterial infection
🔹 Why overlapping respiratory symptoms can contribute to unnecessary antibiotic prescribing
🔹 The three pillars Paul believes every novel point-of-care diagnostic needs to address
🔹 How Lumos is approaching reimbursement, distribution and adoption in the US
Chapters:
01:07 Introduction and Paul Kase’s background
05:43 Lumos Diagnostics and the FebriDx CLIA waiver
08:03 How FebriDx works and the unmet need
09:54 Changing the respiratory testing workflow
14:27 Clinical utility, workflow and reimbursement
20:21 Commercialisation, adoption and distribution
25:14 International expansion and future markets
30:53 Future milestones and driving commercial growth
Guest: Paul Kase
Chief Commercial Officer, Lumos Diagnostics
LinkedIn: https://www.linkedin.com/in/paul-kase-8bb96159/
Host: David Filby
Founder and CEO of Elevra Consulting
LinkedIn: https://www.linkedin.com/in/davidfilby/
🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.